This HTML5 document contains 112 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n29http://linked.opendata.cz/resource/drugbank/drug/DB00929/identifier/pharmgkb/
n28http://linked.opendata.cz/resource/drugbank/drug/DB00929/identifier/wikipedia/
n19http://linked.opendata.cz/resource/AHFS/
n7http://linked.opendata.cz/resource/drugbank/company/
n14http://linked.opendata.cz/resource/mesh/concept/
foafhttp://xmlns.com/foaf/0.1/
n9http://linked.opendata.cz/resource/drugbank/dosage/
n23http://linked.opendata.cz/resource/drugbank/drug/DB00929/identifier/pubchem-compound/
n24http://linked.opendata.cz/resource/drugbank/drug/DB00929/identifier/pubchem-substance/
n25http://linked.opendata.cz/resource/drugbank/drug/DB00929/identifier/kegg-drug/
n16http://bio2rdf.org/drugbank:
n21http://linked.opendata.cz/resource/drugbank/drug/DB00929/identifier/drugbank/
admshttp://www.w3.org/ns/adms#
n17http://www.rxlist.com/cgi/generic/
n4http://linked.opendata.cz/resource/drugbank/patent/
n27http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
n26http://linked.opendata.cz/resource/drugbank/drug/DB00929/identifier/national-drug-code-directory/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n18http://linked.opendata.cz/resource/drugbank/medicinal-product/
n13http://linked.opendata.cz/ontology/mesh/
owlhttp://www.w3.org/2002/07/owl#
n3http://linked.opendata.cz/ontology/drugbank/
n6http://www.drugs.com/cdi/
n8http://linked.opendata.cz/resource/drugbank/property/
n22http://linked.opendata.cz/resource/drugbank/drug/DB00929/identifier/chemspider/
xsdhhttp://www.w3.org/2001/XMLSchema#
n12http://linked.opendata.cz/resource/atc/
n11http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB00929
rdf:type
n3:Drug
n3:description
A synthetic analog of natural prostaglandin E1. It produces a dose-related inhibition of gastric acid and pepsin secretion, and enhances mucosal resistance to injury. It is an effective anti-ulcer agent and also has oxytocic properties. [PubChem]
n3:dosage
n9:271B6336-363D-11E5-9242-09173F13E4C5 n9:271B6337-363D-11E5-9242-09173F13E4C5 n9:271B6338-363D-11E5-9242-09173F13E4C5 n9:271B6339-363D-11E5-9242-09173F13E4C5 n9:271B6334-363D-11E5-9242-09173F13E4C5 n9:271B6335-363D-11E5-9242-09173F13E4C5
n3:generalReferences
# Costa SH, Vessey MP: Misoprostol and illegal abortion in Rio de Janeiro, Brazil. Lancet. 1993 May 15;341(8855):1258-61. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/8098402 # Coelho HL, Teixeira AC, Cruz Mde F, Gonzaga SL, Arrais PS, Luchini L, La Vecchia C, Tognoni G: Misoprostol: the experience of women in Fortaleza, Brazil. Contraception. 1994 Feb;49(2):101-10. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/8143449 # Barbosa RM, Arilha M: The Brazilian experience with Cytotec. Stud Fam Plann. 1993 Jul-Aug;24(4):236-40. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/8212093 # Rocha J: Brazil investigates drug's possible link with birth defects. BMJ. 1994 Sep 24;309(6957):757-8. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/7950553 # Gonzalez CH, Vargas FR, Perez AB, Kim CA, Brunoni D, Marques-Dias MJ, Leone CR, Correa Neto J, Llerena Junior JC, de Almeida JC: Limb deficiency with or without Mobius sequence in seven Brazilian children associated with misoprostol use in the first trimester of pregnancy. Am J Med Genet. 1993 Aug 1;47(1):59-64. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/8368254
n3:group
approved
n3:halfLife
20-40 minutes
n3:indication
Indicated for the treatment of ulceration (duodenal, gastric and NSAID induced) and prophylaxis for NSAID induced ulceration. Misoprostol is also indicated for other uses that are not approved in Canada, including the medical termination of an intrauterine pregnancy used alone or in combination with methotrexate,as well as the induction of labour in a selected population of pregnant women with unfavourable cervices. This indication is avoided in women with prior uterine surgery or cesarean surgery due to an increased risk of possible uterine rupture. Misoprostol is also used for the prevention or treatment of serious postpartum hemorrhage.
n3:manufacturer
n7:271B6324-363D-11E5-9242-09173F13E4C5 n7:271B6323-363D-11E5-9242-09173F13E4C5
owl:sameAs
n16:DB00929 n27:DB00929
dcterms:title
Misoprostol
adms:identifier
n21:DB00929 n22:4445541 n23:5282381 n24:46505041 n25:D00419 n26:0172-4430-49 n28:Misoprostol n29:PA450523
n3:mechanismOfAction
Misoprostol seems to inhibit gastric acid secretion by a direct action on the parietal cells through binding to the prostaglandin receptor. The activity of this receptor is mediated by G proteins which normally activate adenylate cyclase. The indirect inhibition of adenylate cyclase by Misoprostol may be dependent on guanosine-5&rsquo;-triphosphate (GTP). The significant cytoprotective actions of misoprostol are related to several mechanisms. These include: 1. Increased secretion of bicarbonate, 2. Considerable decrease in the volume and pepsin content of the gastric secretions, 3. It prevents harmful agents from disrupting the tight junctions between the epithelial cells which stops the subsequent back diffusion of H<sup>+</sup> ions into the gastric mucosa, 4. Increased thickness of mucus layer, 5. Enhanced mucosal blood flow as a result of direct vasodilatation, 6. Stabilization of tissue lysozymes/vascular endothelium, 7. Improvement of mucosal regeneration capacity, and 8. Replacement of prostaglandins that have been depleted as a result of various insults to the area. Misoprostol has also been shown to increase the amplitude and frequency of uterine contractions during pregnancy via selective binding to the EP-2/EP-3 prostanoid receptors.
n3:packager
n7:271B6322-363D-11E5-9242-09173F13E4C5 n7:271B6320-363D-11E5-9242-09173F13E4C5 n7:271B6321-363D-11E5-9242-09173F13E4C5 n7:271B631E-363D-11E5-9242-09173F13E4C5 n7:271B631F-363D-11E5-9242-09173F13E4C5 n7:271B631C-363D-11E5-9242-09173F13E4C5 n7:271B631D-363D-11E5-9242-09173F13E4C5 n7:271B631A-363D-11E5-9242-09173F13E4C5 n7:271B631B-363D-11E5-9242-09173F13E4C5 n7:271B6318-363D-11E5-9242-09173F13E4C5 n7:271B6319-363D-11E5-9242-09173F13E4C5 n7:271B6316-363D-11E5-9242-09173F13E4C5 n7:271B6317-363D-11E5-9242-09173F13E4C5 n7:271B6314-363D-11E5-9242-09173F13E4C5 n7:271B6315-363D-11E5-9242-09173F13E4C5 n7:271B6312-363D-11E5-9242-09173F13E4C5 n7:271B6313-363D-11E5-9242-09173F13E4C5 n7:271B6310-363D-11E5-9242-09173F13E4C5 n7:271B6311-363D-11E5-9242-09173F13E4C5 n7:271B630E-363D-11E5-9242-09173F13E4C5 n7:271B630F-363D-11E5-9242-09173F13E4C5 n7:271B630C-363D-11E5-9242-09173F13E4C5 n7:271B630D-363D-11E5-9242-09173F13E4C5 n7:271B630A-363D-11E5-9242-09173F13E4C5 n7:271B630B-363D-11E5-9242-09173F13E4C5
n3:patent
n4:5698225 n4:5601843
n3:routeOfElimination
After a single oral dose of misoprostol to nursing mothers, misoprostol acid was excreted in breast milk.
n3:synonym
Cytotec Misoprostolum
n11:hasAHFSCode
n19:56-28-28
n3:foodInteraction
Take with food to decrease the incidence of diarrhea.
n3:proteinBinding
85%
n3:synthesisReference
Salah Ahmed, Raj Mahajan, "Vaginal tablets comprising misoprostol and methods of making and using the same." U.S. Patent US20070071814, issued March 29, 2007.
n13:hasConcept
n14:M0025309
foaf:page
n6:misoprostol.html n17:misopro.htm
n3:IUPAC-Name
n8:271B633E-363D-11E5-9242-09173F13E4C5
n3:InChI
n8:271B6344-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n8:271B6343-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n8:271B6340-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n8:271B6341-363D-11E5-9242-09173F13E4C5
n3:SMILES
n8:271B6342-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n8:271B633C-363D-11E5-9242-09173F13E4C5 n8:271B6354-363D-11E5-9242-09173F13E4C5
n3:logP
n8:271B633A-363D-11E5-9242-09173F13E4C5 n8:271B6355-363D-11E5-9242-09173F13E4C5 n8:271B633D-363D-11E5-9242-09173F13E4C5
n3:logS
n8:271B633B-363D-11E5-9242-09173F13E4C5
n11:hasATCCode
n12:A02BB01 n12:G02AD06
n3:H-Bond-Acceptor-Count
n8:271B634A-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n8:271B634B-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n8:271B6345-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n8:271B6346-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n8:271B6348-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n8:271B6347-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n8:271B6349-363D-11E5-9242-09173F13E4C5
n3:absorption
Misoprostol is extensively absorbed.
n3:affectedOrganism
Humans and other mammals
n3:casRegistryNumber
59122-46-2
n3:category
n3:containedIn
n18:271B6332-363D-11E5-9242-09173F13E4C5 n18:271B6333-363D-11E5-9242-09173F13E4C5 n18:271B6330-363D-11E5-9242-09173F13E4C5 n18:271B6331-363D-11E5-9242-09173F13E4C5 n18:271B632E-363D-11E5-9242-09173F13E4C5 n18:271B632F-363D-11E5-9242-09173F13E4C5 n18:271B632C-363D-11E5-9242-09173F13E4C5 n18:271B632D-363D-11E5-9242-09173F13E4C5 n18:271B632A-363D-11E5-9242-09173F13E4C5 n18:271B632B-363D-11E5-9242-09173F13E4C5 n18:271B6328-363D-11E5-9242-09173F13E4C5 n18:271B6329-363D-11E5-9242-09173F13E4C5 n18:271B6326-363D-11E5-9242-09173F13E4C5 n18:271B6327-363D-11E5-9242-09173F13E4C5 n18:271B6325-363D-11E5-9242-09173F13E4C5
n3:Bioavailability
n8:271B6350-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n8:271B6352-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n8:271B6353-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n8:271B634F-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n8:271B634E-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n8:271B6351-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n8:271B633F-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n8:271B634C-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n8:271B634D-363D-11E5-9242-09173F13E4C5